Abbvie ((ABBV)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie is conducting a Phase 2 clinical study titled A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer. The study aims to evaluate the safety and efficacy of telisotuzumab vedotin, an investigational drug, in treating non-small cell lung cancer (NSCLC) by assessing changes in disease activity and adverse events.
The intervention being tested is telisotuzumab vedotin, administered intravenously. This drug is designed to target and treat NSCLC by inhibiting cancer cell growth.
The study is interventional, with participants randomly assigned to one of three parallel groups, each receiving different doses of the drug. There is no masking involved, and the primary purpose is treatment.
The study began on August 22, 2024, with primary completion expected by August 27, 2025. These dates are crucial for tracking the study’s progress and assessing its outcomes.
This study could significantly impact AbbVie’s stock performance and investor sentiment, as successful results may enhance the company’s market position in the NSCLC treatment landscape. Investors should also consider the competitive environment, as advancements in cancer treatments are highly sought after.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.